Related Experiment Video

Updated: May 24, 2026

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

Infants and Young Children with Children's Interstitial Lung Disease

Robin R Deterding

    Pediatric Allergy, Immunology, and Pulmonology
    |February 15, 2012
    PubMed

    Insights

    Children's interstitial lung disease (chILD) affects infants and young children, presenting unique diagnostic challenges. Early identification and diagnosis are crucial for appropriate management of these rare lung disorders.

    Area of Science:

    • Pediatric Pulmonology
    • Neonatology
    • Rare Diseases

    Background:

    • Interstitial lung disease (ILD) in children, particularly infants, represents a distinct group of disorders.
    • These conditions are linked to lung development and injury, differing from adult ILD.
    • Increased attention is given to infantile ILD due to its unique characteristics and impact.

    Purpose of the Study:

    • To highlight the importance of identifying and diagnosing children's interstitial lung disease (chILD).
    • To review specific chILD disorders common in infancy.
    • To discuss the presentation, evaluation, treatment, and clinical course of these conditions.

    Main Methods:

    • Review of specific infantile chILD disorders including diffuse developmental disorders, growth abnormalities, pulmonary interstitial glycogenosis, neuroendocrine cell hyperplasia of infancy, and surfactant dysfunction mutations.
    • Discussion of presentation, evaluation, and treatment strategies.
    • Brief mention of less common categories and available resources.

    Main Results:

    • Specific infantile chILD disorders require specialized recognition by pediatric specialists.
    • Early diagnosis is critical for effective management and improved outcomes.
    • A range of disorders, from developmental to genetic, fall under the chILD umbrella.

    Conclusions:

    • Recognizing and diagnosing chILD is essential for pediatric pulmonologists, neonatologists, radiologists, and pathologists.
    • Specific infantile disorders like pulmonary interstitial glycogenosis and surfactant dysfunction mutations necessitate tailored approaches.
    • Resources are available to support physicians and families dealing with chILD.

    Related Concept Videos

    Pulmonary Cycle: Exhalation01:17

    Pulmonary Cycle: Exhalation

    In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
    Breathing01:05

    Breathing

    The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
    Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

    Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

    Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
    Pneumonia I: Introduction01:30

    Pneumonia I: Introduction

    Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
    Risk Factors
    Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
    Pneumonia I: Introduction01:29

    Pneumonia I: Introduction

    Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...